CFO of United Therapeutics (UTHR) exercises 10k options, sells 10k shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. He exercised options for 10,000 shares of common stock at an exercise price of $135.42 per share and then sold 10,000 shares in open-market trades at prices ranging from about $569.28 to $580.03. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. After the sales, he directly holds 18,876 shares of United Therapeutics common stock.
Positive
- None.
Negative
- None.
Insights
CFO executes a pre-planned exercise-and-sell, retaining a smaller equity stake.
The CFO of United Therapeutics Corp, James Edgemond, exercised stock options for 10,000 shares at an exercise price of $135.42 per share and sold 10,000 shares in several open-market trades around the high-$570s. The net effect is a routine conversion of options into cash.
The filing notes the exercise and subsequent sales were pursuant to a Rule 10b5-1 trading plan entered into on October 31, 2025, indicating the transactions were pre-scheduled rather than timed discretionarily. Following these trades, Edgemond directly holds 18,876 shares, and no remaining option position is shown in the derivative summary.
Given the pre-planned nature and lack of broader company news in this filing, the event is best viewed as a compensation-related liquidity transaction rather than a signal about United Therapeutics’ operating performance or outlook.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares ($5,748,802)
Net Sell
13 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.75M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 40 | $569.61 | $23K |
| Sale | Common Stock | 281 | $571.1381 | $160K |
| Sale | Common Stock | 1,154 | $571.7623 | $660K |
| Sale | Common Stock | 1,210 | $572.9576 | $693K |
| Sale | Common Stock | 1,860 | $573.9979 | $1.07M |
| Sale | Common Stock | 1,457 | $575.0554 | $838K |
| Sale | Common Stock | 1,354 | $575.9558 | $780K |
| Sale | Common Stock | 1,603 | $577.0106 | $925K |
| Sale | Common Stock | 601 | $577.9251 | $347K |
| Sale | Common Stock | 400 | $579.042 | $232K |
| Sale | Common Stock | 40 | $580.03 | $23K |
Holdings After Transaction:
Stock Option — 92,500 shares (Direct);
Common Stock — 28,876 shares (Direct)
Footnotes (1)
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $577.57 to $578.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $578.59 to $579.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $569.28 to $569.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $570.40 to $571.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $571.40 to $572.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $572.40 to $573.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $573.49 to $574.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $574.49 to $575.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $575.49 to $576.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $576.54 to $577.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 10,000 shares
Exercise price: $135.42 per share
Shares sold: 10,000 shares
+3 more
6 metrics
Options exercised
10,000 shares
Stock option exercise into common stock on April 13, 2026
Exercise price
$135.42 per share
Strike price of stock options exercised by CFO
Shares sold
10,000 shares
Total common shares sold in open-market trades
Sale price range
$569.28–$580.03 per share
Range across multiple sale trades on April 13, 2026
Post-transaction holdings
18,876 shares
Direct common stock held by CFO after all reported trades
Rule 10b5-1 plan date
October 31, 2025
Date CFO entered pre-arranged trading plan covering these trades
Key Terms
Rule 10b5-1 trading plan, Stock Option, open-market sale, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option financial
""security_title": "Stock Option""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
open-market sale financial
""transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What did United Therapeutics (UTHR) CFO James Edgemond report in this Form 4?
He reported exercising options for 10,000 United Therapeutics shares at $135.42 each and selling 10,000 common shares in multiple open-market trades around the high-$570s. The activity reflects an option exercise-and-sell sequence rather than a new open-market share purchase.
What options did the United Therapeutics (UTHR) CFO exercise in this filing?
He exercised stock options covering 10,000 United Therapeutics common shares at an exercise price of $135.42 per share. The options originally had an exercise date of March 15, 2023 and an expiration date of March 15, 2027, as disclosed in the derivative transaction details.
Were the United Therapeutics (UTHR) CFO’s trades under a Rule 10b5-1 plan?
Yes. A footnote states the stock option exercise and subsequent share sales were carried out under a Rule 10b5-1 trading plan entered into on October 31, 2025. Such plans pre-schedule trades, reducing the significance of transaction timing as an indicator of insider sentiment.
Does this United Therapeutics (UTHR) Form 4 show new option grants to the CFO?
No. The Form 4 shows the exercise of previously granted stock options, not new awards. It records converting 10,000 option units into common shares at a $135.42 strike price and then selling 10,000 shares, along with the remaining direct share balance afterward.